Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Both VDZ and IFX are effective in biologic-naïve UC patients, however VDZ demonstrated superior endoscopic outcomes, higher treatment persistence, and a better safety profile, supporting its use as a first-line therapy.

Authors

Institutions

Publication Details

Journal
Gastroenterología y Hepatología
Published
2025-02-21
DOI
https://doi.org/10.1016/j.gastrohep.2025.502396
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Omar Féres, Abel Botelho Quaresma, Katia da Conceição da Silva, Bruno César da Silva et al.
Gastroenterología y Hepatología
Inflammatory Bowel Disease
article

Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

Omar Féres, Abel Botelho Quaresma, Katia da Conceição da Silva, Bruno César da Silva, Lígia Yukie Sassaki, Antônio José Tibúrcio Alves, Júlio Maria Fonseca Chebli, Renata de Medeiros Dutra, José Miguel Luz Parente, Paulo Gustavo Kotze, Munique Kurtz de Mello, Rafael Luís Luporini, Daniéla Oliveira Magro, Rodrigo Galhardi Gasparini, Juarez Roberto de Oliveira Vasconcelos, Eron Fábio Miranda, Marcello Imbrizi, Luiz Ernesto de Almeida Troncon, Guilherme Mattioli Nicollelli, Fernando Jorge Firmino Nóbrega, Cristiane Kibune Nagasako, Sandro da Costa Ferreira, Rogério Serafim Parra, Liliana Andrade Chebli
article en

Abstract

Both VDZ and IFX are effective in biologic-naïve UC patients, however VDZ demonstrated superior endoscopic outcomes, higher treatment persistence, and a better safety profile, supporting its use as a first-line therapy.

Gastroenterología y HepatologíaVol. 48(9)
Universidade Federal de Juiz de Fora (BR), Universidade de Ribeirão Preto (BR), Universidade Federal da Paraíba (BR), Pontifícia Universidade Católica do Paraná (BR), Universidade Federal de São Carlos (BR), Universidade de São Paulo (BR), Universidade Federal do Piauí (BR), Hospital Universitário Lauro Wanderley (BR), Universidade do Oeste de Santa Catarina (BR), Hospital de Clínicas Universidade Federal do Paraná (BR), Universidade do Vale do Itajaí (BR), Clinics Hospital of Ribeirão Preto (BR), Universidade Federal do Paraná (BR), Pontifícia Universidade Católica de Campinas (BR), Universidade Estadual Paulista (Unesp) (BR)
Zero hunger
Openalex Percentile: Top 96%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.